Skip Navigation


Nicotine & Tobacco Research Advance Access originally published online on April 7, 2009
Nicotine & Tobacco Research 2009 11(5):572-576; doi:10.1093/ntr/ntp042
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Article Summary
Right arrow All Versions of this Article:
11/5/572    most recent
ntp042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ebbert, J. O.
Right arrow Articles by Hurt, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebbert, J. O.
Right arrow Articles by Hurt, R. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Combination treatment with varenicline and nicotine replacement therapy

Jon O. Ebbert, Michael V. Burke, J. Taylor Hays and Richard D. Hurt

Jon O. Ebbert, M.D., M.Sc., Mayo Clinic College of Medicine, Rochester, MN
Michael V. Burke, Ed.D., Mayo Clinic College of Medicine, Rochester, MN
J. Taylor Hays, M.D., Mayo Clinic College of Medicine, Rochester, MN
Richard D. Hurt, M.D., Mayo Clinic College of Medicine, Rochester, MN

Corresponding Author: Jon O. Ebbert, M.D., M.Sc., Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA. Telephone: 507-266-1944; Fax: 507-266-7900; E-mail: ebbert.jon{at}mayo.edu


  Abstract

Introduction: A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT).

Methods: We reviewed the clinical experience of two groups of cigarette smokers enrolled in a residential tobacco treatment program: (a) patients receiving combination treatment with varenicline and NRT (N = 104) and (b) usual-care patients receiving treatment before the release of varenicline (N = 135).

Results: Demographic characteristics were similar between the two groups. Among smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse events were experienced by 39% (95% CI = 31%–49%) of patients receiving varenicline and NRT and by 59% (95% CI = 51%–67%) of usual-care patients during the residential program. A total of five patients (5%) discontinued varenicline due to adverse events, compared with one patient in the usual-care group. We did not observe a significant difference in the 30-day point prevalence smoking abstinence rate at 6 months between patients treated with varenicline and NRT (54%; 95% CI = 44%–64%) and usual-care patients (59%; 95% CI = 50%–66%).

Discussion: Our findings suggest that combination therapy with varenicline and NRT is safe and well tolerated among patients in a residential tobacco treatment program.

Received: June 23, 2008; Accepted: November 8, 2008
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
R. D. Hurt, J. O. Ebbert, J. T. Hays, and D. D. McFadden
Treating Tobacco Dependence in a Medical Setting
CA Cancer J Clin, September 1, 2009; 59(5): 314 - 326.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.